Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Inhibikase Therapeutics, Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 14 | 13 | −1 |
| Shares | 747.1K | 429.7K | −317.5K (−42.5%) |
| Value | $2.69M | $597.6K | −$2.10M (−77.8%) |
New holders (1)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 149 | $207 | 0.00% |
Sold out (2)
Institutions that held Inhibikase Therapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Hamilton Lane Advisors LLC | 13,802 | $49.8K |
| Barclays PLC | 11,455 | $41.4K |